21,573 Shares in Eli Lilly and Company $LLY Acquired by PBU The Pension Fund of Early Childhood & Youth Educators

Key Points

• PBU The Pension Fund of Early Childhood & Youth Educators opened a new position in Eli Lilly, buying 21,573 shares valued at about $23.2 million in the fourth quarter. The stake makes LLY its 17th largest holding and about 0.8% of its portfolio.
• Analysts remain broadly positive on Eli Lilly, with a consensus rating of “Moderate Buy” and an average price target of $1,227. Several firms recently raised targets, including Wolfe Research at $1,350 and Guggenheim at $1,183.
• Eli Lilly reported strong quarterly results, beating EPS and revenue estimates with $8.55 per share on $19.8 billion in revenue. The company also raised its FY 2026 EPS guidance and announced a quarterly dividend of $1.73 per share.

PBU The Pension Fund of Early Childhood & Youth Educators purchased a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 21,573 shares of the company's stock, valued at approximately $23,184,000. Eli Lilly and Company comprises about 0.8% of PBU The Pension Fund of Early Childhood & Youth Educators' investment portfolio, making the stock its 17th largest holding.

Several other hedge funds have also added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company in the 4th quarter valued at $25,000. Miller Global Investments LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at $33,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock valued at $32,000 after acquiring an additional 24 shares in the last quarter. Dorato Capital Management acquired a new position in Eli Lilly and Company in the 4th quarter valued at $36,000. Finally, New England Capital Financial Advisors LLC raised its holdings in Eli Lilly and Company by 142.9% in the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company's stock valued at $37,000 after acquiring an additional 20 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. Berenberg Bank lifted their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a "hold" rating in a report on Thursday, February 19th. Guggenheim reaffirmed a "buy" rating and issued a $1,183.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Wolfe Research reaffirmed an "outperform" rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. Cantor Fitzgerald lifted their price objective on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an "overweight" rating in a report on Friday, May 1st. Finally, Loop Capital set a $1,200.00 price objective on Eli Lilly and Company in a report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,227.00.

Eli Lilly and Company Trading Up 0.7%

Shares of LLY opened at $1,133.15 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,166.29. The business's fifty day moving average is $974.59 and its 200-day moving average is $1,013.04. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm has a market cap of $1.07 trillion, a price-to-earnings ratio of 40.25, a PEG ratio of 1.23 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the company posted $3.34 EPS. The company's revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's payout ratio is currently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.